Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on 2 September 2024. The following resolutions were passed at the meeting.

For the period until the next annual general meeting, the extraordinary general meeting resolved to elect John Moore as new ordinary board member.

John Moore is an active investor and entrepreneur in the life science and energy industries. He currently serves as Chairman of two public life science companies Nyrada (NYR-ASX) and Scientific Industries (SCND-OTCQB) and two private companies Trialogics, a clinical trial software business and Cormetech, a leading carbon capture business.

For additional information, please contact:
Patrik Eschricht
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.